Antigen-based immunotherapy (AIT) for autoimmune and allergic disease

Megan Kl MacLeod, Stephen M Anderton

Research output: Contribution to journalLiterature reviewpeer-review

Abstract

Autoimmune and allergic diseases are major causes of morbidity. Antigen-based immunotherapy (AIT) is immunologically the most satisfying means of specifically targeting only those T cells driving disease, thereby inducing antigen-specific immune tolerance, with the lowest adverse risk profile. AIT is highly effective in rodent models of T cell-driven inflammation and is now in clinical trials. The range of approaches to applying AIT in the clinic prevents a consensus on the molecular basis for this form of tolerance. In particular, there has been a paucity of information on how pre-activated effector and memory T cells respond to AIT. New, advanced murine models of AIT are beginning to deliver such information at the cellular, biochemical, transcriptional and epigenetic levels.

Original languageEnglish
Pages (from-to)11-16
Number of pages6
JournalCurrent Opinion in Pharmacology
Volume23
Early online date22 May 2015
DOIs
Publication statusPublished - Aug 2015

Fingerprint Dive into the research topics of 'Antigen-based immunotherapy (AIT) for autoimmune and allergic disease'. Together they form a unique fingerprint.

Cite this